Series Funding Across AI, Robotics and Gene‑Therapy Sectors in Mid‑2026
Recent rounds raised tens to hundreds of millions for AI health platforms, humanoid robotics production, and gene‑therapy development, detailing investors, amounts and intended use.
Compiled automatically from the sources listed below and checked against Hyperuranios' own capital and research data. Every figure here traces to a linked source. Factual errors reported to the contact address are corrected in the article and noted here.
Artificial Intelligence
Arintra closed a Series B round of $25 million, led by Define Ventures with participation from existing backers including Peak XV Partners, YNHH Center for Health Care Innovation, Endeavor Health Ventures, Y Combinator, Counterpart Ventures, Ten13 and Spider Capital. The AI‑driven medical coding platform will use the capital to broaden its revenue‑assurance platform, extend coverage across more enterprise health systems and add clinical and specialty coding capabilities, building on a service that claims a 5.1% lift in compliant revenue capture and a 43% drop in coding‑related denials [1].
Runable announced a $21 million Series A round co‑led by Susquehanna Venture Capital and Nexus Venture Partners, with existing investors Together Fund and Array VC also participating. The round values the Bengaluru‑based agentic AI startup at $65 million post‑money and will fund expansion of growth channels, enhancement of campaign measurement, and development of AI agents that can autonomously adjust marketing campaigns. Runable also plans to scale its free Runable Academy and hire across engineering, machine learning, product, growth and support functions [3][5].
Robotics
Wonik Robotics raised 350 billion KRW (approximately $253 million) in a growth‑equity round to build mass‑production facilities for humanoid robots and robot hands. The National Growth Fund led the round with a 150 billion KRW convertible‑preferred investment, while private investors contributed the remaining 200 billion KRW. Funds will finance a new robot‑hand production plant and an AI Transformation centre in Wanju, as well as in‑house development of core components and research, aiming to ease the actuator and hand cost bottleneck that currently dominates humanoid hardware expenses [2].
Motion secured $2 million in pre‑seed financing, led by Extantia Capital with participation from Norrsken Evolve, to expand its Humanoids‑as‑a‑Service platform across European factories. The capital will be used to scale the robot fleet, convert five paid pilots in Belgium into full commercial deployments, grow the team and increase the fleet throughout the Benelux region. Motion’s hardware‑agnostic service bundles robot selection, data collection, task training, IT integration, financing, insurance, compliance and maintenance under a predictable monthly fee, targeting labour shortages in European manufacturing [4][6].